Bradley Duffy

Array ( [id] => 13479121 [patent_doc_number] => 20180291103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST PROGRAMMED DEATH-LIGAND (PDL1) [patent_app_type] => utility [patent_app_number] => 15/748438 [patent_app_country] => US [patent_app_date] => 2016-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15748438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17875566 [patent_doc_number] => 11447567 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Antibody constructs for FLT3 and CD3 [patent_app_type] => utility [patent_app_number] => 15/225568 [patent_app_country] => US [patent_app_date] => 2016-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 51534 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15225568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11401743 [patent_doc_number] => 20170022282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'Humanized Anti-CD70 Binding Agents and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/217109 [patent_app_country] => US [patent_app_date] => 2016-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 30265 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15217109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11670054 [patent_doc_number] => 20170158773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'IMMUNOGLOBULIN VARIANTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/217838 [patent_app_country] => US [patent_app_date] => 2016-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 36964 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15217838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522099 [patent_doc_number] => 20180312592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => CYSTEINE-SUBSTITUTED IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 15/745351 [patent_app_country] => US [patent_app_date] => 2016-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15745351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436101 [patent_doc_number] => 20170037121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES' [patent_app_type] => utility [patent_app_number] => 15/210218 [patent_app_country] => US [patent_app_date] => 2016-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 51961 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15210218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436134 [patent_doc_number] => 20170037153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES' [patent_app_type] => utility [patent_app_number] => 15/210199 [patent_app_country] => US [patent_app_date] => 2016-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 52024 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15210199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12227542 [patent_doc_number] => 09914777 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-13 [patent_title] => 'Human CD3 binding antibody' [patent_app_type] => utility [patent_app_number] => 15/205629 [patent_app_country] => US [patent_app_date] => 2016-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 29 [patent_no_of_words] => 21220 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15205629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13326019 [patent_doc_number] => 20180214547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND IL-6 [patent_app_type] => utility [patent_app_number] => 15/743013 [patent_app_country] => US [patent_app_date] => 2016-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15743013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114956 [patent_doc_number] => 20160311930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'Dual Specificity Antibody Fusions' [patent_app_type] => utility [patent_app_number] => 15/058460 [patent_app_country] => US [patent_app_date] => 2016-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15350 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15058460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13672831 [patent_doc_number] => 20160375149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES [patent_app_type] => utility [patent_app_number] => 15/195571 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107657 [patent_doc_number] => 20160304627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'ACCEPTOR FRAMEWORK FOR CDR GRAFTING' [patent_app_type] => utility [patent_app_number] => 15/195411 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10367 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12490101 [patent_doc_number] => 09994645 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => Acceptor framework for CDR grafting [patent_app_type] => utility [patent_app_number] => 15/193432 [patent_app_country] => US [patent_app_date] => 2016-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9809 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15193432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793337 [patent_doc_number] => 20190010207 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => PD-1-CD28 FUSION PROTEINS AND THEIR USE IN MEDICINE [patent_app_type] => utility [patent_app_number] => 15/737877 [patent_app_country] => US [patent_app_date] => 2016-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12814018 [patent_doc_number] => 20180163176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => MODIFIED NK-92 CELLS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/531109 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15531109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13493115 [patent_doc_number] => 20180298100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => Combination Therapy for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 15/580969 [patent_app_country] => US [patent_app_date] => 2016-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15580969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16816836 [patent_doc_number] => 11001642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same [patent_app_type] => utility [patent_app_number] => 15/579616 [patent_app_country] => US [patent_app_date] => 2016-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 76 [patent_no_of_words] => 28190 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11092358 [patent_doc_number] => 20160289326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor' [patent_app_type] => utility [patent_app_number] => 15/172666 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 19209 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15172666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13479073 [patent_doc_number] => 20180291079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => ANTI-GD3 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 15/575707 [patent_app_country] => US [patent_app_date] => 2016-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15575707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350266 [patent_doc_number] => 20160369007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'IMMUNOGLOBULIN VARIANTS WITH ALTERED BINDING TO PROTEIN A' [patent_app_type] => utility [patent_app_number] => 15/159151 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 20662 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15159151 [rel_patent_id] =>[rel_patent_doc_number] =>)